Cost-Utility Analysis and Value-Based Pricing of Digital Therapeutics for Pulmonary Rehabilitation in Patients With Chronic Respiratory Disease: A Multicenter Randomized Controlled Trial
Author(s)
Hyeonjung Park, B.Pharm (Oriental)1, Minseol Jang, PharmD1, Daehyun Kim, PharmD1, Chul Kim, M.D., PhD2, Jun Hyeong Song, M.D., M.S.2, Ju Hyun Oh, M.D.3, Chin Kook Rhee, M.D., PhD4, Jae Ha Lee, M.D., PhD5, HeeEun Choi, M.D., M.S.6, Hae Sun Suh, MA, MS, PhD7;
1Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Korea, Republic of, 2Department of Rehabilitation Medicine, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea, Republic of, 3Department of Pulmonary and Critical Care Medicine, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea, Republic of, 4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, 5Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine,, Busan, Korea, Republic of, 6Department of Physical Medicine and Rehabilitation, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea, Republic of, 7College of Pharmacy, Kyung Hee University, Seoul, Korea, Republic of
1Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Korea, Republic of, 2Department of Rehabilitation Medicine, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea, Republic of, 3Department of Pulmonary and Critical Care Medicine, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea, Republic of, 4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, 5Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine,, Busan, Korea, Republic of, 6Department of Physical Medicine and Rehabilitation, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea, Republic of, 7College of Pharmacy, Kyung Hee University, Seoul, Korea, Republic of
Presentation Documents
OBJECTIVES: This study aimed to evaluate the cost-effectiveness of digital therapeutics (DTx) for respiratory rehabilitation in patients with chronic respiratory disease (CRD), including chronic obstructive pulmonary disease, and to explore value-based pricing (VBP) for DTx through cost-utility analysis based on a randomized controlled trial.
METHODS: This economic evaluation was based on a randomized controlled trial involving 84 participants. Patients were randomized into the DTx group (n=43) or control (n=41) group for an 8-week rehabilitation program. Data on medical costs, drug prescriptions, and quality of life were collected. Costs were estimated from the perspective of the Korean healthcare system, and health outcomes were measured using the COPD Assessment Test (CAT). CAT scores were mapped to the European quality of life 5-dimensions, 3-level utilities, following a literature review to estimate quality-adjusted life years (QALY). VBP was investigated within the cost-effective range of DTx. Scenario, subgroup, deterministic analyses, and probabilistic sensitivity analysis with 1,000 simulations were conducted to test the robustness.
RESULTS: Using DTx, QALY increased by 0.0096 at an additional cost of $85.33, resulting in an incremental cost-utility ratio of $8,922 per QALY. The maximum cost-effective price for an 8-week DTx program was $192 based on VBP analysis. Probabilistic sensitivity analysis indicated a 60.2% probability of DTx being cost-effective, assuming a willingness-to-pay threshold of $19,410 per QALY, which corresponded to Korea’s Gross Domestic Product per capita in 2006.
CONCLUSIONS: DTx for pulmonary rehabilitation was more cost-effective compared to standard rehabilitation. These findings highlight the value of DTx for patients with CRD and support its integration into current healthcare frameworks as a resource-efficient option for managing CRD.
METHODS: This economic evaluation was based on a randomized controlled trial involving 84 participants. Patients were randomized into the DTx group (n=43) or control (n=41) group for an 8-week rehabilitation program. Data on medical costs, drug prescriptions, and quality of life were collected. Costs were estimated from the perspective of the Korean healthcare system, and health outcomes were measured using the COPD Assessment Test (CAT). CAT scores were mapped to the European quality of life 5-dimensions, 3-level utilities, following a literature review to estimate quality-adjusted life years (QALY). VBP was investigated within the cost-effective range of DTx. Scenario, subgroup, deterministic analyses, and probabilistic sensitivity analysis with 1,000 simulations were conducted to test the robustness.
RESULTS: Using DTx, QALY increased by 0.0096 at an additional cost of $85.33, resulting in an incremental cost-utility ratio of $8,922 per QALY. The maximum cost-effective price for an 8-week DTx program was $192 based on VBP analysis. Probabilistic sensitivity analysis indicated a 60.2% probability of DTx being cost-effective, assuming a willingness-to-pay threshold of $19,410 per QALY, which corresponded to Korea’s Gross Domestic Product per capita in 2006.
CONCLUSIONS: DTx for pulmonary rehabilitation was more cost-effective compared to standard rehabilitation. These findings highlight the value of DTx for patients with CRD and support its integration into current healthcare frameworks as a resource-efficient option for managing CRD.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE41
Topic
Economic Evaluation
Topic Subcategory
Trial-Based Economic Evaluation
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)